BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review

Background: The combination therapy of BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been approved as a first-line treatment for metastatic melanoma with BRAF V600 mutants. Recently, BRAF mutations have been divided into three subtypes based on biochemical and signaling characteristics. Un...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Simeng, Yang, Zichang, Cheng, Yu, Guo, Xiaoyu, Liu, Chang, Wang, Shuo, Zhang, Lingyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853440/
https://www.ncbi.nlm.nih.gov/pubmed/36686670
http://dx.doi.org/10.3389/fphar.2022.1019217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853440/
https://www.ncbi.nlm.nih.gov/pubmed/36686670
http://dx.doi.org/10.3389/fphar.2022.1019217

Ejemplares similares